LGVN Stock Overview
A clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Longeveron Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.56 |
| 52 Week High | US$6.40 |
| 52 Week Low | US$0.77 |
| Beta | 0.37 |
| 1 Month Change | 11.43% |
| 3 Month Change | 6.12% |
| 1 Year Change | -10.86% |
| 3 Year Change | -98.14% |
| 5 Year Change | n/a |
| Change since IPO | -97.89% |
Recent News & Updates
Recent updates
ELPIS II And Alzheimer Programs Will Accelerate FDA Approval
Apr 15 Successful trial enrollment and regulatory designations could accelerate Longeveron's market entry and future revenue growth through streamlined FDA pathways and partnerships.Is Longeveron (NASDAQ:LGVN) In A Good Position To Invest In Growth?
Mar 05
Will Longeveron (NASDAQ:LGVN) Spend Its Cash Wisely?
Nov 17Shareholder Returns
| LGVN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -10.9% | 2.8% | 3.0% |
| 1Y | -10.9% | -6.8% | 10.1% |
Return vs Industry: LGVN underperformed the US Biotechs industry which returned -6.8% over the past year.
Return vs Market: LGVN underperformed the US Market which returned 10.1% over the past year.
Price Volatility
| LGVN volatility | |
|---|---|
| LGVN Average Weekly Movement | 10.4% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: LGVN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: LGVN's weekly volatility has decreased from 25% to 10% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 25 | Mohamed Wa'el Hashad | longeveron.com |
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 1 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer’s disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Longeveron Inc. Fundamentals Summary
| LGVN fundamental statistics | |
|---|---|
| Market cap | US$23.29m |
| Earnings (TTM) | -US$24.62m |
| Revenue (TTM) | US$2.39m |
9.7x
P/S Ratio-0.9x
P/E RatioIs LGVN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LGVN income statement (TTM) | |
|---|---|
| Revenue | US$2.39m |
| Cost of Revenue | US$508.00k |
| Gross Profit | US$1.88m |
| Other Expenses | US$26.51m |
| Earnings | -US$24.62m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 08, 2025
| Earnings per share (EPS) | -1.65 |
| Gross Margin | 78.76% |
| Net Profit Margin | -1,029.39% |
| Debt/Equity Ratio | 0% |
How did LGVN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/04 15:56 |
| End of Day Share Price | 2025/05/02 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Longeveron Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Boobalan Pachaiyappan | H.C. Wainwright & Co. |
| Jason McCarthy | Maxim Group |